LIB Therapeutics Announces Abstracts Accepted for Presentation at the American College of Cardiology Scientific Session 2024

CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company advancing Lerodalcibep, a novel, LDL-cholesterol lowering, third-generation PCSK9 inhibitor, today announced acceptance of two abstracts from the recently completed Phase 3 registration-enabling LIBerate program for presentation at the American College of Cardiology 2024 in Atlanta, Georgia on April 6-8, 2024.

• Late-Breaking Clinical Trials II Main Tent - Oral Presentation

“Randomized, Double-blind, Placebo-controlled, Phase 3, Study to Evaluate Lerodalcibep Long-term Efficacy and Safety in Patients with, or at Very-high or High Risk, for Cardiovascular Disease on Stable Lipid-lowering Therapy”; presented by Dr. Eric Klug, April 7, 8:45 AM - 8:55 AM EST

• Moderated Poster Theater 08 - Oral Presentation

“Long-Term Efficacy and Safety of Lerodalcibep in Heterozygous Familial Hypercholesterolemia”; presented by Dr. Evan Stein, April 7, 11:00 AM - 11:10 AM EST

About Lerodalcibep

Lerodalcibep, a novel, potent, small binding protein, third-generation PCSK9 inhibitor, has been developed as a more convenient, once-monthly dose in a small injection volume and with long-ambient stability. Combined with sustained LDL-C reductions demonstrated in clinical trials, lerodalcibep is expected to expand treatment options for the millions of patients around the world with atherosclerotic cardiovascular disease (ASCVD), and those at very high and high risk for ASCVD, including the 30 million individuals with more severe inherited high-cholesterol called familial hypercholesterolemia (FH).

The global Phase 3 LIBerate program with over 2,700 patients enrolled a diverse population of patients with CVD, without CVD at very high and high risk for CVD, including heterozygous and homozygous familial hypercholesterolemia (FH). Key registration placebo-controlled trials included Lerodalcibep once-monthly for up to 52 weeks, and over 2,400 patients continued in the 72-week open-label extension trial. LIB is preparing a biologics license application (BLA) for Lerodalcibep and plans for regulatory submission in 2024.

About LIB Therapeutics Inc.

LIB Therapeutics is a privately-held, late-stage biopharmaceutical company dedicated to bringing novel, safe and convenient subcutaneous and oral PCSK9 inhibitors to the millions of patients with cardiovascular disease and the 30 million individuals with familial hypercholesterolemia (FH), who require additional large reductions in low density lipoprotein-cholesterol (LDL-C) despite maximally tolerated statins and other lipid lowering agents.

For more information, please visit: www.libtherapeutics.com.